These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1159 related items for PubMed ID: 16490582

  • 1. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM, Shi M, Buckley BJ, Kwarcinski MA.
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
    Grosset AB, Roberts MS, Woodson ME, Shi M, Swanton RE, Reder RF, Buckley BJ.
    J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK, Bijur PE, Baccelieri A, Gallagher EJ.
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
    [Abstract] [Full Text] [Related]

  • 4. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A, Ma C, Ahdieh H, Galer BS.
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [Abstract] [Full Text] [Related]

  • 5. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM, Messina J, Xie F, Hale M.
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [Abstract] [Full Text] [Related]

  • 6. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH, Gould E.
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
    Aqua K, Gimbel JS, Singla N, Ma T, Ahdieh H, Kerwin R.
    Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
    [Abstract] [Full Text] [Related]

  • 8. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
    Hale M, Khan A, Kutch M, Li S.
    Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
    [Abstract] [Full Text] [Related]

  • 9. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J, Sittl R.
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [Abstract] [Full Text] [Related]

  • 10. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A, Bozkaya D, Fleischmann J, Dubois D, Sabatowski R, Caro JJ.
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [Abstract] [Full Text] [Related]

  • 11. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days.
    Riff DS, Duckor S, Gottlieb I, Diamond E, Soulier S, Raymond G, Boesing SE.
    Clin Ther; 2009 Oct; 31(10):2072-85. PubMed ID: 19922878
    [Abstract] [Full Text] [Related]

  • 12. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R, Lorenz V, Korak-Leiter M, Kager I, Sittl R.
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [Abstract] [Full Text] [Related]

  • 13. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R, Kayser H, Sittl R.
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [Abstract] [Full Text] [Related]

  • 14. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.
    Pain Pract; 2008 Jun; 8(4):287-313. PubMed ID: 18503626
    [Abstract] [Full Text] [Related]

  • 15. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
    Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT, Dornseif BE, Damask MC.
    J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain.
    Nicholson B, Ross E, Sasaki J, Weil A.
    Curr Med Res Opin; 2006 Aug; 22(8):1503-14. PubMed ID: 16870075
    [Abstract] [Full Text] [Related]

  • 17. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.
    Hagen NA, Babul N.
    Cancer; 1997 Apr 01; 79(7):1428-37. PubMed ID: 9083166
    [Abstract] [Full Text] [Related]

  • 18. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR.
    Clin Ther; 2007 Oct 01; 29(10):2179-93. PubMed ID: 18042474
    [Abstract] [Full Text] [Related]

  • 19. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
    Nalamachu SR, Kutch M, Hale ME.
    J Pain Symptom Manage; 2012 Dec 01; 44(6):852-65. PubMed ID: 22795050
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C, Failde I, Micó JA, Neira M, Sánchez-Magro I.
    Clin Ther; 2005 Apr 01; 27(4):451-62. PubMed ID: 15922818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.